Active Ingredient History
Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 2)
Amphetamine-Related Disorders (Phase 1)
Anxiety (Phase 2)
Cardiomyopathy, Dilated (Phase 4)
Cardiovascular Diseases (Phase 4)
Cocaine-Related Disorders (Phase 2)
Coronary Disease (Phase 3)
COVID-19 (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetic Nephropathies (Phase 4)
Erectile Dysfunction (Phase 1)
Essential Hypertension (Phase 4)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Heart Failure (Phase 3)
Hypercholesterolemia (Phase 3)
Hypertension ()
Kidney Calculi (Phase 3)
Methamphetamine (Phase 1/Phase 2)
Mood Disorders (Phase 1)
Myocardial Infarction (Phase 3)
Myocardial Ischemia (Phase 3)
Paraganglioma (Phase 3)
Pheochromocytoma (Phase 4)
Prostate (Phase 4)
Prostatic Hyperplasia (Phase 4)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Rhinitis, Allergic (Phase 4)
Smoking (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 1)
Urinary Bladder Neck Obstruction (Phase 4)
Urinary Bladder, Overactive (Phase 4)
Vascular Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
